Member Info for potnak

Well PH mates must not have much cash. Look at the volume. Tiny amount of shares traded. It just standard for AIM. Parkers retweet this morning was the biggest clue yet that preclinical has gone well. He said about to finish preclinical! I'd say that means in the next few weeks, days even. I would make sense to announce this before the AGM and Investor Meet event.

About to finish preclinical is the phrase for me. Its going to be on time. Not sure if it's RNS able but successfully passing preclinical massively derisks the compound, especially with the known issues of other TYK2 compounds. It will be the catalyst to a deal being made.

Essentially, yes. 1801 would treat the symptoms, what ever virus causes the symptoms.

Essentially, yet. 1801 would treat the symptoms, what ever virus cause the symptoms.

Not to burst your bubble but it we want sdc1801 to be used for Covid, it'll be even more experimental than the vaccines. Trust the science for all the drugs/vaccines or not at all. Its the same approval process for all.

Not saying you shouldn't ask but one look at the PH news pages tells me why they were appointed. This is what they do for clients. https://www.peelhunt.com/news

I'm on the fence with the tox results. I think they will come before the end of the year, mainly because it still stated that in the Edison report and that was edited recently. So unless they planned to shoot themselves in the foot again. The results will be out soon, possibly before the AGM, tomorrow even? However, I'm on the fence as to the news adding value. It's a big hurdle but is it already priced in? We know the new dates for a trial are H2 2022 and the tox results aren't going to change that. So are new investors going to buy and hold at 10p or will they take the risk and wait until the CTA is lodged. There will be a spike of sorts, so it might be a good trading opportunity for the traders amongst us? I've been reading all the posts over the last week or so and lots here seem to be disregarding what the company have told us. Why are they expecting news or a rerate? Other than the tox results, I'm not expecting any news until at least spring next year unless Sierra pull their fingers out? I'm relaxed here and looking for a late 22 or early 23 exit. Just my view, not after getting in at a lower price, just being realistic.

Pure speculation on my part but I was thinking that we couldn't reach MTD with the tablet but a new formula that will also work in capsule form might have given them the option to kill two birds with one stone. I'm thinking the capsule was an afterthought but worth delaying the progress by 9 months.

Tox report is only part of the data package. IMO, this is why they gave a 9 month window for the CTA. It gives them time to get all the data together. Tox studies, pre clinical studies, manufacturing etc. You then have something to tout to the investors or buyers. And if it doesn't happen then Peel Hunt will raise enough for Sareum to put 1801\2 into P1 and P1b trials. They have to get this report out before year end. If they do, confidence will come flooding back and we'll be back at 8p, maybe more.

Absolutely, jashar! The small buy by Parker and the Edison report turned around what could've been a disaster for the SP. I wonder, Was the report hastily authored? Or they just got the timing spectacularly wrong.

Yes, first person dosed. The milestone is nothing in the grand scheme of things but I don't think SRA737 is fully priced into the sp. Once we have movement again, the market will reassess the value of Sareum. Fast track status could mean £70 million and royalties coming our way in less than 3 years. Thoths 28p will be had just SRA737.

James is correct. The board have no knowledge of what is happening with SRA737. They will get the news when we do. I personally think we'll get 737 news in January, trial start dates in Q2 and how sierra will fund the trials. If they get fast track status, This could possibly push SAR past 10,15 or even 20p. And commercialisation in 2 years. Sareum should be comfortably sitting at 8.25p, the last subscription price. They will be when news flow starts again.

NDR, personally. I'd rather we partner up early to derisk my investment but I think we are going to go into P1 with funds from equity placing that Peel will broker, that's what they do. It will still derisk us but may dilute the shares. Hopefully, Peel can place a high SP to protect and crystalise the value. Funds and II's will never buy in until the SP is stable.

For those new to the share and for those LTH who forgot. Here is a link to another Edison report. https://www.edisongroup.com/publication/treading-the-tyk2-trail/29435

Scroll down to exhibit 10 for some example deal sizes. We are right in the preclinical\P1 sweet spot.

Once this tox study is done and released, we may get news on which indication they will aim for and the size of the market if successful.

for those that missed the link in all the noise earlier. https://www.edisongroup.com/publication/sdc-1801s-clinical-plan-modified/30232

Th Edison Report came out today (obviously prompted by Sareum) so hopefully, that means they are going to make this particular milestone.

Hot Black. Its in the Edison report.

The company’s core asset, the TYK2/JAK1 inhibitor SDC-1801, is on track to conclude preclinical
studies, with the completion of the final toxicology and safety studies expected by management by
the end of calendar year 2021.

I'm not holding my breath for this release or any SP rerate if they do release it. However, it would be good if they could get the news out before the AGM.

I missed the tox results bit. Have they said tox results this year? Was that in the Results statement?

Yes, it does mean that but we already know there is no immediate news due. They told us the timescales. I just hope they stick to them. The only news that might come early is SRA737. The board have no inside knowledge of this deal. They will find out the next steps when we do and as Thoth said earlier. It will probably be sooner rather than later. Peel might bring something to the table in along the lines of a corporate placing, this will be multiple millions, maybe tens of millions, hopefully at a premium higher the share price. The Edison report published today tells you just about everything you need to know. Buy the dips now, knowing that at most you should only have to wait 9 months for a significant rerate from today's price. For balance, also know you could lose the lot. This is AIM, you know.